PATENT CLAIM ANALYSIS

Application Number: 16012372
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["514", "183000"]

Abstract:
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Claim (Index 11):
A method of treating patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy who are not homozygous for the UTG1A1*28 allele, the method comprising intravenously administering to the patient in need thereof an antineoplastic therapy once every two weeks, the antineoplastic therapy consisting of:\n a. administering liposomal irinotecan as an intravenous infusion over 90 minutes in an amount providing 70 mg/m 2  of irinotecan free base, the liposomal irinotecan composition comprising irinotecan encapsulated in irinotecan liposomes having an area under the plasma concentration curve extrapolated to time infinity (AUC 0-\u221e ) of about 1091-1705 [h\u00b7\u03bcg/mL]; followed by b. 200 mg/m 2  of the (1) form of leucovorin; and c. 2,400 mg/m 2  of 5-fluorouracil.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.22857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15241128', '14406776', '14851111', '14844500', '14812950']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8297901090765857
- 35 USC 102 Novelty (BERT): 0.7399744701884498
- Combined Prediction Score: 0.820808545187772
- Mean Citation Score: 628.0000880000001
- Max Citation Score: 844.3667
- Similarity Product: 819.4951187591313

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test